GlassScriptPhysician profile
William Shaw Hunter
NPI 1043821572
$4,215.49
in general payments reported to CMS, 2019-2025
15 companies · $882 in 2025
The $882 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.72 · 2022: $46.65 · 2023: $447 · 2024: $2,792 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,235 · Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,235.27 |
| Food and Beverage | $1,885.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,262.36 | 2024 | |
| Boston Scientific Corporation | $1,203.57 | 2023-2024 | Watchman Flx, Watchman Access System, Resonate El Icd Vr |
| Medtronic, INC. | $897.48 | 2022-2025 | Linq II, Micra |
| Janssen Pharmaceuticals, INC | $275.71 | 2023-2024 | Xarelto |
| Biosense Webster, INC. | $174.77 | 2024 | Carto 3, Qdot Micro Catheter |
| Amgen INC. | $88.77 | 2023-2024 | Repatha |
| Pfizer INC. | $88.06 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $53.90 | 2024-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $45.10 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.06 | 2024 | Jardiance |
| Heartflow, INC. | $24.53 | 2023 | Ffrct |
| Ancora Heart, INC. | $24.38 | 2024 | Accucinch |
| Seqirus USA INC | $17.79 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.08 | 2023 | |
| Abbvie INC. | $15.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.